

# Apple Health PDL Drug Class Motions

# Ophthalmic Agents : Ectoparasiticides

---

- ▶ **Motion:** I move that all products in the Ophthalmic Agents : Ectoparasiticides class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Flynn**

# Antidepressants : GABA Receptor Modulator - Neuroactive Steroid

---

- ▶ **Motion:** I move that all products in the Antidepressants : GABA Receptor Modulator - Neuroactive Steroid class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Taylor**
- ▶ **2<sup>nd</sup>: Weiland**

# Antiparkinson Agents

---

- ▶ Adenosine Receptor Antagonists
- ▶ Dopaminergics
- ▶ Monoamine Oxidase Inhibitors (MAOI)

# Antiparkinson Agents

---

**Motion:** I move that all products in the drug classes listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Flynn**
- ▶ **2<sup>nd</sup>: MacKay**

# Gastrointestinal Agents : Ilean Bile Acid Transporter Inhibitors

---

- ▶ **Motion:** I move that all products in the Gastrointestinal Agents : Ilean Bile Acid Transporter Inhibitors class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Flynn**

# Glaucoma Agents

---

- ▶ Adrenergic Agents
- ▶ Adrenergic Agents Combinations
- ▶ Beta – Blockers
- ▶ Beta – Blockers Combinations
- ▶ Carbonic Anhydrase Inhibitors
- ▶ Kinase Inhibitors
- ▶ Miotics
- ▶ Prostaglandins

# Glaucoma Agents

---

**Motion:** I move that all products in the drug classes listed on slide 7 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Weiland**
- ▶ **2<sup>nd</sup>: Barkett**



# Hematological Agents - Misc : Compliment Inhibitors - Injectable

---

- ▶ **Motion:** I move that all products in the Hematological Agents - Misc : Compliment Inhibitors - Injectable class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flynn**
- ▶ **2<sup>nd</sup>: Weiland**

# Oncology Agents : Antineoplastics Combinations - Oral

---

- ▶ **Motion:** I move that all products in the Oncology Agents : Antineoplastics Combinations – Oral class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Taylor**
- ▶ **2<sup>nd</sup>: Hudson**

# Gastrointestinal Agents : Short Bowel Syndrome

---

- ▶ **Motion:** I move that all products in the Gastrointestinal Agents : Short Bowel Syndrome class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: MacKay**
- ▶ **2<sup>nd</sup>: Hudson**

# Hematological Agents - Misc : Aminolevulinate Synthase 1-Directed SIRNA

---

- ▶ **Motion:** I move that all products in the Hematological Agents - Misc : Aminolevulinate Synthase 1-Directed SIRNA class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Taylor**
- ▶ **2<sup>nd</sup>: Weiland**

# Hematological Agents : Pyruvate Kinase Activators

---

- ▶ **Motion:** I move that all products in the Hematological Agents : Pyruvate Kinase Activators class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Barkett**

# Hematological Agents : Other

---

- ▶ **Motion:** I move that all products in the Hematological Agents : Other class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: NO REVIEW NEEDED**
- ▶ **2<sup>nd</sup>:**

# Neuromuscular Agents : Antimyasthenic/Cholinergic Agents

---

- ▶ **Motion:** I move that all products in the Neuromuscular Agents : Antimyasthenic/Cholinergic Agents class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: MacKay**
- ▶ **2<sup>nd</sup>: Flynn**

# Ophthalmic Agents : Nerve Growth Factors

---

- ▶ **Motion:** I move that all products in the Ophthalmic Agents : Nerve Growth Factors class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Hudson**
- ▶ **2<sup>nd</sup>: Weiland**



# Vasopressors : Misc - Oral

---

- ▶ **Motion:** I move that all products in the Vasopressors : Misc – Oral class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flynn**
- ▶ **2<sup>nd</sup>: MacKay**

# AHDPL Classes

---

## ▶ Allergy

- ▶ Allergenic Extracts / Biologicals – Oral

## ▶ Asthma and COPD Agents

- ▶ Anticholinergics
- ▶ Inhaled Corticosteroid Combinations
- ▶ Inhaled Corticosteroids
- ▶ Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations
- ▶ Long Acting Muscarinic Agents
- ▶ Phosphodiesterase 4 Inhibitors

## ▶ Atopic Dermatitis Agents

- ▶ Immunosuppressive Agents - Topical Combinations

# AHDPL Classes

---

## ▶ Endocrine And Metabolic Agents

- ▶ GAA Deficiency Agents
- ▶ Growth Hormone Releasing Hormones (GHRH)
- ▶ Mucopolysaccharidosis Agents
- ▶ Somatostatic Agents
- ▶ Urea Cycle Disorder Agents – Oral
- ▶ Vasopressin Receptor Antagonists - Oral

## ▶ Hematopoietic Agents

- ▶ Erythroid Maturation Agents
- ▶ Erythropoiesis-Stimulating Agents (ESAS)

# AHDPL Classes

---

- ▶ Hematopoietic Agents (Cont.)
  - ▶ Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
- ▶ Neuromuscular Agents
  - ▶ Systemic Lupus Erythematosus Agents
- ▶ Oncology Agents
  - ▶ Androgen Biosynthesis Inhibitors – Oral
  - ▶ Antiandrogens – Oral
  - ▶ Antiestrogens – Oral
  - ▶ Cyclin Dependent Kinases (CDK) Inhibitors – Oral
  - ▶ Hedgehog Pathway Inhibitors – Oral

# AHDPL Classes

---

- ▶ Oncology Agents (Cont.)
  - ▶ Imidazotetrazines – Oral
  - ▶ Methyltransferase Inhibitors
  - ▶ MTOR Kinase Inhibitors – Oral
  - ▶ Retinoids – Oral
  - ▶ Topoisomerase Inhibitors – Oral
- ▶ Respiratory Agents
  - ▶ Pulmonary Fibrosing Agents
- ▶ Smoking Deterrents
  - ▶ Misc – Other

# AHDPL Classes

---

**Motion:** I move that all products in the drug classes listed on slides 18-21 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Chawla**
- ▶ **2<sup>nd</sup>: Barkett**